These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Bonome T; Lee JY; Park DC; Radonovich M; Pise-Masison C; Brady J; Gardner GJ; Hao K; Wong WH; Barrett JC; Lu KH; Sood AK; Gershenson DM; Mok SC; Birrer MJ Cancer Res; 2005 Nov; 65(22):10602-12. PubMed ID: 16288054 [TBL] [Abstract][Full Text] [Related]
4. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. Bignotti E; Tassi RA; Calza S; Ravaggi A; Romani C; Rossi E; Falchetti M; Odicino FE; Pecorelli S; Santin AD Gynecol Oncol; 2006 Nov; 103(2):405-16. PubMed ID: 16725184 [TBL] [Abstract][Full Text] [Related]
5. Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary. May T; Virtanen C; Sharma M; Milea A; Begley H; Rosen B; Murphy KJ; Brown TJ; Shaw PA Gynecol Oncol; 2010 Apr; 117(1):9-17. PubMed ID: 20117829 [TBL] [Abstract][Full Text] [Related]
6. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Santin AD; Zhan F; Bellone S; Palmieri M; Cane S; Bignotti E; Anfossi S; Gokden M; Dunn D; Roman JJ; O'Brien TJ; Tian E; Cannon MJ; Shaughnessy J; Pecorelli S Int J Cancer; 2004 Oct; 112(1):14-25. PubMed ID: 15305371 [TBL] [Abstract][Full Text] [Related]
7. Identification of differentially expressed genes using an annealing control primer system in stage III serous ovarian carcinoma. Kim YS; Hwan JD; Bae S; Bae DH; Shick WA BMC Cancer; 2010 Oct; 10():576. PubMed ID: 20969748 [TBL] [Abstract][Full Text] [Related]
8. Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-beta signaling in ovarian cancer. Sunde JS; Donninger H; Wu K; Johnson ME; Pestell RG; Rose GS; Mok SC; Brady J; Bonome T; Birrer MJ Cancer Res; 2006 Sep; 66(17):8404-12. PubMed ID: 16951150 [TBL] [Abstract][Full Text] [Related]
9. Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression. Motamed-Khorasani A; Jurisica I; Letarte M; Shaw PA; Parkes RK; Zhang X; Evangelou A; Rosen B; Murphy KJ; Brown TJ Oncogene; 2007 Jan; 26(2):198-214. PubMed ID: 16832351 [TBL] [Abstract][Full Text] [Related]
10. Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. Gilks CB; Vanderhyden BC; Zhu S; van de Rijn M; Longacre TA Gynecol Oncol; 2005 Mar; 96(3):684-94. PubMed ID: 15721412 [TBL] [Abstract][Full Text] [Related]
11. Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer. Chien J; Fan JB; Bell DA; April C; Klotzle B; Ota T; Lingle WL; Gonzalez Bosquet J; Shridhar V; Hartmann LC Gynecol Oncol; 2009 Jul; 114(1):3-11. PubMed ID: 19410283 [TBL] [Abstract][Full Text] [Related]
15. Development of a highly specialized cDNA array for the study and diagnosis of epithelial ovarian cancer. Sawiris GP; Sherman-Baust CA; Becker KG; Cheadle C; Teichberg D; Morin PJ Cancer Res; 2002 May; 62(10):2923-8. PubMed ID: 12019173 [TBL] [Abstract][Full Text] [Related]
16. Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma. Liu JF; Hirsch MS; Lee H; Matulonis UA Gynecol Oncol; 2009 Dec; 115(3):401-6. PubMed ID: 19796795 [TBL] [Abstract][Full Text] [Related]
17. Differential gene expression analysis of ovarian cancer in a population isolate. Grazio D; Pichler I; Fuchsberger C; Zolezzi F; Guarnieri P; Heidegger H; Scherer A; Engl B; Messini S; Egarter-Vigl E; Pramstaller PP Eur J Gynaecol Oncol; 2008; 29(4):357-63. PubMed ID: 18714569 [TBL] [Abstract][Full Text] [Related]
18. Gene expression profiling of advanced-stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumor progression and prognosis. Yoshihara K; Tajima A; Komata D; Yamamoto T; Kodama S; Fujiwara H; Suzuki M; Onishi Y; Hatae M; Sueyoshi K; Fujiwara H; Kudo Y; Inoue I; Tanaka K Cancer Sci; 2009 Aug; 100(8):1421-8. PubMed ID: 19486012 [TBL] [Abstract][Full Text] [Related]
19. Expression of Interactive Genes Associated with Apoptosis and Their Prognostic Value for Ovarian Serous Adenocarcinoma. Shin K; Kim KH; Yoon MS; Suh DS; Lee JY; Kim A; Eo W Adv Clin Exp Med; 2016; 25(3):513-21. PubMed ID: 27629740 [TBL] [Abstract][Full Text] [Related]
20. Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer. Ouellet V; Guyot MC; Le Page C; Filali-Mouhim A; Lussier C; Tonin PN; Provencher DM; Mes-Masson AM Int J Cancer; 2006 Aug; 119(3):599-607. PubMed ID: 16572426 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]